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Introduction 
Schizophrenia, a neurodevelopmental disease, has  “afflicted humans 
since the beginning of written history.” The afflicted patients were often times 
perceived to be prophets or seers and other times to be manifestations of the 
devil (Tamminga & Holcomb, 2005). In the 15th century, it was believed that 
cutting certain nerves in the brain could eliminate excess emotion and stabilize a 
personality of the mentally ill, so lobotomy – a form of psychosurgergy – was 
practiced (Tartakovsky, 2011). It was not until the late 19th century that 
compassionate treatment for these patients surfaced. Schizophrenia, which 
literally means splitting of the mind, has severe psychopathology with three 
facets: positive symptoms, negative symptoms, and cognitive deficits. The 
present understanding of schizophrenia is one which, describes patients in terms 
of their psychopathology, impairment of function and ability to sustain a normal 
life style and role in society. The severity and experiences range from person to 
person: one individual may experience a single episode and continue with his or 
her life, whereas the majority, however, will experience multiple relapses with 
autonomous functions in between and will need medications and support. 
Unfortunately, the course of schizophrenia is life-long and often times, the 
disease may have a rather fast onset and symptoms initially showing in late 
teens and early adult years (Tamminga & Holcomb, 2005). Schizophrenia is 
observed in 1% of the general population but other factors can contribute to 
increase the risk of schizophrenia.  
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Positive Symptoms 
Positive symptoms present an excess or distortion of normal functions; the 
main symptoms include delusions, hallucinations, thought disorder and 
disorganized behavior. 
Delusions are simply beliefs and convictions which, are not based on 
reality, and they are a result of misinterpreting perceptions and experiences and 
this is the most common schizophrenic symptom. In hallucinations, these patient 
claim to hear sounds and see things that do not exist, and hearing sounds is the 
most common form of hallucination among schizophrenics. Thought disorder 
refers to the difficulty in schizophrenic patient to organize thoughts and speaking. 
He or she may often times stop midsentence to collect his thought process. And 
disorganized behavior alludes to simple childlike silliness to intense agitation 
(Mayo Clinic, 2012). 
Negative Symptoms 
Negative symptoms are the critical features of schizophrenia and they 
highlight an absence of normal mental functions; they consist of affective 
flattening (lack of emotional expression), alogia (lack of logic), avolition (inability 
to utilize free will), anhedonia (inability to feel pleasure), and attention impairment 
(Wyss, et al., 2013).  
Negative symptoms often cause social impairment which translates into 
low success rate in social and professional life and this explains much of the 
long-term morbidity and poor functional outcomes of those afflicted with 
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schizophrenia impairment (Wyss, et al., 2013). Much evidence has been 
accumulated over time to support that negative symptoms is a facet of its own in 
schizophrenia (Blanchard & Cohen, 2006).  
Cognitive Deficit 
 The third facet of schizophrenia is cognitive deficits, which previously was 
clustered with negative symptoms, but with recent clinical studies, it is now 
highlighted as a third major diagnostic category of schizophrenia. Furthermore, it 
is also considered to be the core deficit of the disorder (Castner, et al., 2004). 
Cognitive dysfunction includes but is not limited to working memory defects, 
attention dysfunction, verbal and visual learning and memory, processing speed 
and social learning (Tamminga & Holcomb, 2005). The severity of cognitive 
dysfunction is the best predictor of “social functioning, unemployment and even 
relapse” (Castner, et al., 2004). 
Since working memory is vital for “integrity of thought process,” it can be 
concluded that malfunction of the neural circuitry of working memory may be the 
underlying cause of cognitive deficits and associated thought disorders in 
schizophrenia (Castner, et al., 2004). Functions that are associated with frontal 
cortex are abnormal (i.e., verbal fluency, spatial performance, and pattern 
recognition) and long-term memory is affected (Tamminga & Holcomb, 2005). 
Additionally, schizophrenic patients perform poorly on tasks which, required 
vigilance or paying attention, and these are particularly associated with the 
anterior cingulated (Tamminga & Holcomb, 2005). Furthermore, deficits due to 
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malfunctioning of the hippocampus may occur, affecting explicit memory, verbal 
memory and working memory. An impacted working memory can justify the lack 
of organization in thought processes because the ability to hold information “on-
line” is rather crucial for the organization of future thoughts and even associating 
them with recent past (Tamminga & Holcomb, 2005).  
Treatments 
Treatment of schizophrenia has evolved over the centuries: in 15th 
century, schizophrenic were considered to be evil and possessed and were 
treated with lobotomy; however, as time went on, it was discovered that they 
were mentally ill (Tamminga & Holcomb, 2005).  In early 1930, they were treated 
with unusual and unlikely methods such as fever therapies, adrenalectomy, and 
vasectomy; these were all based on pure speculations. Towards the end of 
World War II, with the overwhelming necessity for treatment, Reserpine was 
administered with some improvement but it also came with significant side effect. 
Chlorpromazine, however, was the first effective and selective antipsychotic drug 
and it was discovered by “clinical serendipity” (Tamminga & Holcomb, 2005). 
The discovery that chlorpromazine and other phenothiazines showed 
dramatic effects in control of psychosis which led to the convening of the 
American College of Neuropsychopharmacology (ACNP) (Moghaddam & Javitt, 
2012). Implementation of these treatments allowed many patients to be 
deinstitutionalized and to carry on with their daily lives (Tamminga & Holcomb, 
2005). Shortly thereafter, a linkage between antipsychotic drugs and blockade of 
 
 
6 
 
D2-Type dopamine receptor was found which allowed for the production of the 
drugs, phenothaizine and non-phenothiazines. Fifty years later, the primary 
treatment for schizophrenia remains practically unchanged: clozapine, 
(developed in 1961), is the most efficacious drug. There have been numerous 
attempts to mimic a drug of the same result without its “hematological and 
orthostatic side effects” and failures normally observed in negative symptoms 
and cognitive deficits (Moghaddam & Javitt, 2012). There is not a consensus on 
one particular antipsychotic which can sufficiently treat debilitating cognitive 
dysfunction due to schizophrenia (Castner, et al., 2004); however, a realization 
which has been unanimously reached is that, “not only are we in need of 
alternative medications but [also] alternative targets” (Moghaddam & Javitt, 
2012). 
Genetics 
The disease is characterized by the three facets – positive, negative and 
cognitive symptoms. Population, families and twin studies indicate that 
schizophrenia is “highly heritable”; however, no single gene can induce such 
effects. Rather, the disease is byproduct of synergistic interactions of various 
genes and environmental factors. With studies in the field of association and 
linkage, over dozens of risks genes for schizophrenia have been identified 
(Lisman, et al., 2008). 
While genes play a significant role in development and occurrence of 
schizophrenia, research is also being conducted with a focus on neurotransmitter 
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systems and evidence continues to point abnormalities present in more than one 
system. One thing which is certain is that it is not one simple system that is 
malfunctioning and rather it is a combination of glutamate, GABA, dopamine and 
acetylcholine system malfunction that is contributing and giving rise to this 
disease (Lisman, et al., 2008). 
This evidence essentially suggests the idea that there is a dire need to 
take an integrative approach towards schizophrenia that takes into the account 
the synergistic way those genes and neurotransmitters work to produce this 
illness (Lisman, et al., 2008). 
 Neurodevelopment  
A schizophrenic brain is distinct from a typical brain and it has been 
considered a neurodevelopmental disorder for past 25 years. It can be drawn 
that aberrant development during fetal, childhood or adolescent periods can 
potentially account for these pathological changes. Further, the popular 
perspective is that the neurodevelopment changes can be explained by genetic 
predisposition, early adverse event such as “mid-gestational insults.” It is widely 
agreed that adolescence is a critical period but also that pre and perinatal 
development are susceptible time periods which, may contribute to onset of 
schizophrenia. Recent studies are showing that schizophrenia is not restricted to 
the womb but rather it is a process, which continues post-birth as well as in 
adolescence and early adulthood. This provides an opportunity for potential 
perturbation during these periods because it is believed that these periods 
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contribute to the onset of schizophrenia and therefore serve as critical 
timeframes to target (Catts, et al., 2013). 
Prenatal period is a critical and sensitive time in which exposure in the 
uterus can impact the course of development and the offspring. For example, 
early immune system development gives rise to changes in the fetal immune 
system. There is evidence from epidemiological and genetic studies that suggest 
that immune dysregulation in the developing brain might play a role in the 
development of schizophrenia. (Marques, et al., 2013). The timing of immune 
dysregulation with “respect to gestational age and neurological development of 
fetus” creates a sensitive window of vulnerability which can be targeted 
(Marques, et al., 2013). The fetal immune system is particularly vulnerable to 
disruptions caused by environmental factors such as malnutrition, toxins, stress 
and anxiety (Marques, et al., 2013). 
Impairments in the neurodevelopment translate into various cognitive 
domains such as verbal memory, processing speed and the other symptoms 
discussed previously.  
KCNQ Potassium Channels 
KCNQ potassium channels (Kv7) are voltage-dependent potassium 
channels “composed of homo- and hetero-tetrameric complexes of five different 
KCNQ subunits” – Kv7.1 – Kv7.5. All these subunits except Kv7.1 are strongly 
expressed in neuronal tissue including neocortex and hippocampus and “their 
activation is responsible for the generation of M current, an inhibitory K+ current 
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regulating repetitive action potential discharges” (Sotty, et al.  2009). There have 
been many attempts in the past to discover pharmacological KCNQ modulators 
as a method to treat the central nervous system diseases; retigabine was the first 
and it is a KCNQ potassium channel opener (Sotty, et al., 2009). 
All subtypes of KCNQ channels start to open around -60 mV; they can 
also be considered as non-activating leaky K+ channels at relevant resting 
potentials and a fraction of the may undergo steady-state inactivation. Given 
these characteristics, they are able to produce the “underlying subthreshold M-
Current” which then can stabilize the neuronal resting potential. In turn, these are 
thought to inhibit excitability and essentially put action potential to halt upon the 
exposure to an excitatory stimulus (Hansen, et al., 2008). 
Hypothesis 
We have identified the KCNQ (Kv7) potassium channels as a potential 
molecular target for the development of pharmacotherapies for schizophrenia. 
KCNQ potassium channels are slow activating, slow-deactivating, voltage-
dependent potassium channels that play a significant role in regulation of 
neuronal excitability and neurotransmitter release. These ion channels are widely 
distributed in the brain, including in regions implicated in pathologies of 
schizophrenia, such as the prefrontal cortex, hippocampus, and nucleus 
accumbens. The data from our laboratory suggests that modulation of KCNQ 
potassium channel function may be exploited for the treatment of behavioral 
symptoms of schizophrenia. The studies described here examine the role of 
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KCNQ potassium channel blockers in modulation of behavioral deficits observed 
in the phencyclidine (PCP) animal model of schizophrenia. 
Methods 
Animals 
Male Sprague-Dawley rats from Harlan Laboratories weighing 300-450 
grams were used for these experiments.  Rats were individually housed in 
standard rat cages with 12/12 hrs light cycle with lights on at 7:00 A.M., food and 
water were available ad libitum. All experiments were conducted during the light 
cycle. 
Prepulse inhibition 
Rats were placed into chambers and exposed to a weak stimulus pulse of 
sound (2, 6, or 15 db prepulse), which typically inhibits startle reaction to a 
stronger stimulus (110 db pulse). This experiment tests sensorimotor gating, 
which is disrupted in schizophrenic patients. 
Delayed-Alternation Working Memory Paradigm 
The rats were habituated to the animal colony for about a week before 
training began. These rats had no prior exposure to the food reward (Apple 
Jacks) nor the T-Maze apparatus. Subsequently, animals were habituated to an 
empty maze for three days (10 minutes/day). After initial habituation, the rats 
were trained to perform in the maze in a forced, alternating fashion (20 trials/day 
for 5 days). Following forced alternation, rats were trained to perform in  
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forced/choice trials. In this stage, the rat is forced to one side (picked at random), 
allowed to eat the reward, then is returned to the “home” area and following a 3 
seconds delay is permitted to enter the unobstructed maze in order to identify 
that the reward is present in the opposite arm (20 seconds between individual 
rounds). 
Drugs 
The phencyclidine (PCP) was obtained from the National Institutes of 
Health and dissolved in saline. All other drugs were obtained commercially. 
DMP543 was dissolved in 40% DMSO in saline. The PCP was administered at 
1.5 mg/kg, subcutaneously and the DMP453 at 0.15 mg/kg, subcutaneously.  
Results 
Delayed-Alternation Memory Task 
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The data show that rats performed at about ≥90% accuracy when treated 
with Vehicle/Saline which, serves as control group. Animals injected with 
DMP543/Saline alone do not show any decrease in performance compared with 
the control group. However, when PCP is administered to these animals, there is 
a significant decrease in the performance roughly to 60-70%. But DMP543 can 
reverse the PCP effects on memory in these animals, an increase to ~85% is 
observed. 
 
 Prepulse Inhibition 
 
 
This graph shows the percent prepulse inhibition recorded at prepulses of 
2, 6, and 15 db. As clearly depicted by the graph, it shows when PCP is 
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administered, the prepulse inhibition is decreased significantly. However, when 
the KCNQ potassium channel blocker, XE991, is used, there is a significant 
improvement in the prepulse inhibition.  
The results of these studies do in fact support our hypothesis that blocking 
the KCNQ potassium channel in the brain can reverse the detrimental effects of 
PCP on normal animal behaviors. A significant reversal is observed in these 
animals in their behavior including working memory and prepulse inhibition of 
startle response. 
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